297 related articles for article (PubMed ID: 15705904)
1. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
2. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.
Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA
Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the activity of the RSK-specific inhibitor, SL0101.
Smith JA; Maloney DJ; Hecht SM; Lannigan DA
Bioorg Med Chem; 2007 Jul; 15(14):5018-34. PubMed ID: 17512736
[TBL] [Abstract][Full Text] [Related]
4. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA
Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840
[TBL] [Abstract][Full Text] [Related]
5. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a potent and selective inhibitor of p90 Rsk.
Maloney DJ; Hecht SM
Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148
[TBL] [Abstract][Full Text] [Related]
7. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
[TBL] [Abstract][Full Text] [Related]
8. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
9. Divergent off-target effects of RSK N-terminal and C-terminal kinase inhibitors in cardiac myocytes.
Stathopoulou K; Schobesberger S; Bork NI; Sprenger JU; Perera RK; Sotoud H; Geertz B; David JP; Christ T; Nikolaev VO; Cuello F
Cell Signal; 2019 Nov; 63():109362. PubMed ID: 31344438
[TBL] [Abstract][Full Text] [Related]
10. Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK.
Xu YM; Smith JA; Lannigan DA; Hecht SM
Bioorg Med Chem; 2006 Jun; 14(11):3974-7. PubMed ID: 16524738
[TBL] [Abstract][Full Text] [Related]
11. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
12. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.
Utepbergenov D; Derewenda U; Olekhnovich N; Szukalska G; Banerjee B; Hilinski MK; Lannigan DA; Stukenberg PT; Derewenda ZS
Biochemistry; 2012 Aug; 51(33):6499-510. PubMed ID: 22846040
[TBL] [Abstract][Full Text] [Related]
13. Paving the way for targeting RSK in cancer.
Romeo Y; Roux PP
Expert Opin Ther Targets; 2011 Jan; 15(1):5-9. PubMed ID: 20958120
[TBL] [Abstract][Full Text] [Related]
14. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Implications of RSK1-3 in Human Breast Cancer.
Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024
[TBL] [Abstract][Full Text] [Related]
16. The RSK family of kinases: emerging roles in cellular signalling.
Anjum R; Blenis J
Nat Rev Mol Cell Biol; 2008 Oct; 9(10):747-58. PubMed ID: 18813292
[TBL] [Abstract][Full Text] [Related]
17. Regioselective Synthesis of a
Li Y; Sandusky ZM; Vemula R; Zhang Q; Wu B; Fukuda S; Li M; Lannigan DA; O'Doherty GA
Org Lett; 2020 Feb; 22(4):1448-1452. PubMed ID: 32009414
[TBL] [Abstract][Full Text] [Related]
18. Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.
Hilinski MK; Mrozowski RM; Clark DE; Lannigan DA
Bioorg Med Chem Lett; 2012 May; 22(9):3244-7. PubMed ID: 22464132
[TBL] [Abstract][Full Text] [Related]
19. The MAP kinase ERK5 binds to and phosphorylates p90 RSK.
Ranganathan A; Pearson GW; Chrestensen CA; Sturgill TW; Cobb MH
Arch Biochem Biophys; 2006 May; 449(1-2):8-16. PubMed ID: 16626623
[TBL] [Abstract][Full Text] [Related]
20. Regulation and function of the RSK family of protein kinases.
Romeo Y; Zhang X; Roux PP
Biochem J; 2012 Jan; 441(2):553-69. PubMed ID: 22187936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
